Innovation in Allografts Translational Grants

Innovation in Allografts Translational Grants is sponsored by MTF Biologics. This program supports high-impact translational and clinical research that advances allograft tissue science and improves patient outcomes. Proposed research must utilize allograft tissues or allograft-derived materials and include a clear, credible pathway toward clinical translation.

125 MAY STREET | EDISON, NJ 08837 | MTFBIOLOGICS. ORG A NON -PROFIT ORGANIZATION Equal Opportunity Employer # Innovation in Allograft Translational MTF Biologics is pleased to announce the 2026 Innovation in Allograft Translational Research Grants . This program supports high‑impact translational and clinical research that advances allograft tissue science and improves patient outcomes.

Proposed research must utilize allograft tissues or allograft‑derived materials and include a clear, credible pathway toward clinical translation. Projects focused solely on autologous, synthetic‑only, or non‑allograft‑centered technologies are out of scope.

Clinical areas of interest include orthopaedics, plastic and reconstructive surgery, aesthetics, surgical soft ‑tissue repair, abdominal wall reconstruction, and wound care, as well as any other specialty area where allograft transplantation technologies can drive meaningful improvement.

Topic areas of interest include: • Novel allograft uses : New indications or techniques utilizing HCT/P allografts or extracellular matrices with a defined translation strategy. • Combination approaches : Allografts combined with biomaterials, biologics, or other modalities to enhance mechanical, biological, or clinical performance.

• Allograft ‑centric technologies : Methods that enhance natural properties of allografts, including advanced processing, preservation, activation, or decellularization/recellularization technologies.

• Tissue engineering and regenerative medicine : Use of allograft tissues or matrices as preferred platforms for engineered constructs, regenerative therapies, or combination • Real ‑world evidence and health economics : Outcomes research, comparative effectiveness, registry analyses, and cost ‑effectiveness studies focused on allograft • Extracellular vesicles and secretome : Investigation of exosomes, microvesicles, or secretome derived from allograft tissues to drive repair and regeneration.

• Computational and precision approaches : AI/ML, genomics, donor profiling, or decision ‑support tools that improve donor selection, graft performance prediction, and patient ‑matched allograft therapies. Other relevant research topics aligned with the program objectives will be considered.

A NON -PROFIT ORGANIZATION > Equal Opportunity Employer Qualified applicants may apply under one of the following tracks: • Junior Investigator: One‑year, $75,000 award for investigators without prior major • Established Investigator : Three‑year, $225,000 award for investigators with prior major • Career Development Award : Three‑year, $225,000 award for a post‑residency M. D. or D.

O. at an MTF -Biologics Academic Member Institution . Letters of Intent (LOI) Due Date - March 23 , 202 6 Announcement of LOI positive review and Request for full proposal – by end of April 202 6 Full Proposal Due Date (if LOI is approved) - June 15, 202 6 Announcement of Awards to Grant Recipients – by end of October 202 6 Please visit https://proposalcentral.

com/ and search for MTF Biologics for application forms and instructions.